Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools like dissectors, graspers, scissors, needle holders, fan retractors, cautery devices, and insufflation needles. Furthermore, CYduct supplies illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps, alongside insufflators. For surgical specialties, their portfolio features laparoscopic instruments designed for general surgery, lymphadenectomy, gynecology, and thorascopy. Complementing these are rigid scopes (like laparoscopes, operative scopes, and cystoscopes) with their corresponding accessories, as well as trocar and cannula sets, video carts, and both insulated and non-insulated instrument handles. Uniquely, the company also provides instrumentation tailored for veterinary applications. Established in 1986, CYduct Diagnostics, Inc. is headquartered in Westport, Connecticut. The firm was formerly known as Solos Endoscopy, Inc., before adopting its current name in December 2020.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.